CMAX Clinical Research has been recognised on the national stage, winning the 2025 Australian Export Award for Professional Services and cementing its position as one of Australia’s most influential contributors to global early-phase clinical research.

CSL has released landmark five-year clinical results for its gene therapy HEMGENIX, confirming long-term durability, safety, and substantial clinical benefit for adults living with haemophilia B.

Chimeric Therapeutics (ASX:CHM) has achieved a significant regulatory milestone, announcing it has secured FDA Orphan Drug Designation for its lead candidate, CHM CDH17, in the treatment of gastric cancer.

Imugene (ASX:IMU) has taken a significant step toward potential commercialisation of its allogeneic CAR-T therapy azercabtagene zapreleucel, after receiving supportive written minutes from the US Food and Drug Administration outlining a clear route to a Phase 3 registrational trial.

Australian scientists have identified, for the first time, specific genetic changes that sharply increase the risk of the most sight-threatening forms of age-related macular degeneration, offering a crucial lead for developing new therapies that could intervene before irreversible vision loss occurs.

Australia’s biotechnology sector has welcomed a new entrant with the launch of Evinco Therapeutics, a Melbourne-based company developing advanced immune therapies aimed at transforming the treatment of Alzheimer’s disease and other neuroinflammatory conditions.

Executive remuneration in Australia’s health care and biotechnology sectors rose modestly in the last financial year, with a 7.2 per cent increase in total CEO pay, according to the 2025 ASX Health Care and Biotechnology Remuneration Report.

Australia’s emerging medtech sector has received a significant boost, with a new report revealing the scale of commercial, clinical and translational progress achieved through MTPConnect’s Clinical Translation and Commercialisation – Medtech (CTCM) Program.

Noxopharm (ASX:NOX) has reached a significant milestone in its first-in-human trial of SOF-SKN, announcing that the initial multiple-dose cohort in the HERACLES study has been completed with no safety concerns identified.

LTR Pharma (ASX:LTP) has secured ethics approval for the next stage of clinical development of its fast-acting erectile dysfunction therapy, paving the way for recruitment to begin early next year and marking another step in the company’s expansion into global markets.

A team of Melbourne researchers has uncovered how subtle electrical signals can direct stem cell behaviour, an advance that could reshape the future of tissue engineering, regenerative medicine, and the development of lab-grown organs.

Island Pharmaceuticals (ASX:ILA) has strengthened its financial position, announcing that directors and substantial shareholders have exercised more than 14.4 million options, delivering just over $1 million in new capital to support the company’s antiviral development programs.

BCAL Diagnostics (ASX:BDX) has taken a significant step toward strengthening clinical confidence in its flagship breast cancer diagnostic, announcing national ethics approval for a large-scale registry that will track outcomes for up to 24,000 Australian women.

AusBiotech is pleased to share an opportunity for Australia’s life sciences community to hear directly from AstraZeneca’s global Search and Evaluation leaders.